undamentalytics Newsletter
Sign in

Onkure Therapeutics, Inc. (OKUR) stock

Add to watchlist

Add holding +

NASDAQ: OKUR Nasdaq Biotechnology Next results ~November 5, 2026

Onkure Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.

Who’s trading

What company insiders, investment funds and members of Congress have been doing with the stock, from their own filings.

  • Insiders0 buying, 2 selling0 purchases and 8 sales by directors and officers, last 12 monthsInsider trades
  • Funds52 adding, 17 cuttingOf 14 active managers that changed their stake, 10 added; quarter to June 30, 2026Fund buyers and sellers

The Fundamentalytics view

Next results ~November 5, 2026 (estimated)

Current signal Results well ahead of expectations: Reported earnings per share beat the analysts' consensus estimate by 42% in the quarter to 2026-06-30, the 3rd beat in the last four quarters.

Assembled from SEC-filed figures — the full workings are on this page and in our methodology. Observations, not recommendations.

Highlights

How we pick these

Strengths

Nothing in Onkure Therapeutics, Inc.'s latest figures clears our strength thresholds.

Things to watch

  • Results due soon. Results are expected around 5 November; the share price can move sharply on the day.
  • Volatile shares. Over the past year the shares showed annualised volatility of 70% and a beta of 1.2 against the S&P 500.

Latest results

Earnings per share
-$0.31 against an average estimate of -$0.54: beat by 42.1%
Share reaction
+3.5% in the first session after the results on August 4, 2026, against +1.6% for the S&P 500

Onkure Therapeutics' figures from its SEC filings and results release; estimates are the analysts' average. Not a recommendation.

Price chart

  • 1 day-1.1%
  • 1 week+4.6%
  • 1 month+1.2%
  • This year-10.7%
  • 1 year-23.6%
  • 5 years-96.4%
  • S&P 500 this year+11.2%

Closing prices to 2026-11-02. Price change only, dividends excluded.

Loading chart…

Third-party market data · may be delayed

At a glance

Trailing twelve months, from SEC filings

Earnings

Last results
August 4, 2026
Next results (est.)
November 5, 2026

News & updates

Updated October 31, 2026

Company announcements, filed results and changes that matter to shareholders.

  1. Leadership
  2. Results

Refreshed hourly when new source data is available. Summaries are checked against company releases and SEC filings. Company announcement headlines are labelled when a checked summary is unavailable.

Valuation

Onkure Therapeutics, Inc. valuation models and calculator

No model value for Onkure Therapeutics, Inc. at the moment. Current status: limited reported history: available models are shown without a Buy/Hold/Sell rating. Available reported financials are shown below.

Fundamentalytics rating

model v1.6 · 2026-11-03

Not rated: limited reported history: available models are shown without a Buy/Hold/Sell rating.

Moat

Not assessed: fewer than five years of comparable figures in the filings. AI disruption exposure for this industry: Medium.

A rules-based reading of reported figures, not a forecast and not investment advice. How the score is built: methodology.

Forecasts and guidance

Analysts' consensus

Fiscal yearEPSGrowthRevenueGrowth
Current −$1.83 +58% $250000 0%
Next −$1.53 +17% $666670 +167%

How the EPS forecast has moved

The consensus EPS forecast for the current fiscal year is −26.9% on 90 days ago. In the last 30 days, 1 analyst raised Onkure Therapeutics, Inc.'s forecast and 0 cut it.

Consensus EPS forecast Onkure Therapeutics, Inc., last 90 days
−$3.00 −$2.00 −$1.00 $0.00 90 days ago 60 days ago 30 days ago 7 days ago Now Current fiscal year, 90 days ago: −$2.50 Current fiscal year, 60 days ago: −$2.50 Current fiscal year, 30 days ago: −$2.50 Current fiscal year, 7 days ago: −$1.96 Current fiscal year, Now: −$1.83 −$1.83 Next fiscal year, 90 days ago: −$2.13 Next fiscal year, 60 days ago: −$2.13 Next fiscal year, 30 days ago: −$2.13 Next fiscal year, 7 days ago: −$1.96 Next fiscal year, Now: −$1.53 −$1.53

Average of analysts' published estimates (third-party data).

View chart data
Period Current fiscal yearNext fiscal year
90 days ago −$2.50−$2.13
60 days ago −$2.50−$2.13
30 days ago −$2.50−$2.13
7 days ago −$1.96−$1.96
Now −$1.83−$1.53

Earnings against estimates

Quarter toEstimateActualSurprise
Jun 2026 −$0.54 −$0.31 +42.1%
Mar 2026 −$0.74 −$1.11 −49.5%
Dec 2025 −$1.15 −$0.99 +14.1%
Sept 2025 −$1.20 −$1.09 +9.0%

Adjusted EPS as companies report it, against the average analyst estimate.

Analyst recommendations

6 analysts, Oct 2026
Buy583%
Hold117%
Sell00%

Monthly trend

  1. Oct 2026516
  2. Sep 2026516

Counts of recommendations published by analysts covering Onkure Therapeutics, Inc., by month. Source: Aggregated broker recommendations (third-party data). Aggregated counts only: we do not reproduce any firm's recommendation or price target, and these are not Fundamentalytics ratings.

Positioning

Short interest
3.8%
of tradable shares
Days to cover
3.5
at average volume
Short interest, 1 month
+1%
to October 15, 2026
Held by institutions
93%
of shares
Held by insiders
10.2%
of shares
Employees
45
full time

Consensus figures average analysts' published estimates (third-party data); guidance is the company's own. Neither is our forecast. Short interest is reported twice a month and lags. Market data may be delayed.

This section is general information, not investment advice or a personal recommendation, and it does not take account of your objectives or circumstances. Forecasts and guidance are estimates, not promises: companies miss their own guidance and analysts' figures are often revised. Prices can fall as well as rise, and you can lose money. See our disclaimer.

Share-price performance

Market data may be delayed

Return and risk by year

Calendar year 20222023202420252026 to date
Return
OKUR−73%−31%−46%−66%−11%
Industry peers (median)−56%−17%−28%−5%−27%
S&P 500−18%+26%+25%+18%+11%
Months that ended higher
OKUR42%58%50%25%36%
S&P 50042%67%75%75%46%
Largest fall from a high during the year
OKUR−80%−87%−59%−80%−60%
S&P 500−25%−10%−8%−19%−9%

Worst fall since April 8, 2021: 99% from April 8, 2021 to May 14, 2025. Getting back needed a 8097% gain, and the shares have not yet recovered.

Price behaviour

52-week range
$2.10 – $5.27
From 52-week high
−50.9%
vs 50-day average
−10.0%
vs 200-day average
−28.2%
Volatility (1 year)
70%
Beta vs S&P 500
1.21

Volatility is the annualised standard deviation of daily returns. Beta 1.5 means the shares typically moved 1.5% for each 1% move in the S&P 500 over the past year. Prices to November 2, 2026.

Share price after results

Next day
6 up, 6 down
typical move ±7.0%
After a week
6 up, 6 down
typical move ±14.2%
After a month
8 up, 4 down
typical move ±13.8%
Results releasedNext dayS&P 500 next day5 days21 days
August 4, 2026 +3.5% +1.6% +1.7% −11.9%
May 5, 2026 −11.5% +2.2% −26.3% −6.5%
March 12, 2026 +7.1% −2.1% +24.1% +26.1%
November 6, 2025 −2.0% −1.0% +4.7% +14.0%
August 12, 2025 +18.2% +1.4% +35.0% +20.2%
May 6, 2025 −14.1% −0.4% −26.7% +13.9%
March 10, 2025 −1.4% −3.5% −4.0% −38.8%
August 13, 2024 +9.7% +2.0% +17.9% +5.2%
May 7, 2024 +5.8% +0.1% −6.4% −1.7%
March 28, 2024 +3.0% −0.2% +3.6% +1.2%
November 13, 2023 −0.9% +1.8% −2.2% +21.1%
August 10, 2023 −6.3% 0.0% −18.1% +5.1%

From the close before the release date to the close 1, 5 and 21 trading days after it, so releases before the open and after the close are both captured. Past moves don't predict future ones.

Fundamentals

Data: SEC EDGAR XBRL company facts (as filed in 10-K/10-Q); forms . Generated November 3, 2026. Definitions in our methodology.

Who owns it

Funds buying and selling
Reported value
$159M
Institutions reporting
75
Shares held vs prior quarter
▲ 27.1%
Positions opened / closed
31 / 8

Top buyers and sellers, Q2 2026: 52 institutions bought and 17 sold ; the biggest buyer was Blackrock, Inc (+1.5M shares) and the biggest seller Foresite Capital Management Vi LLC (−1.4M). See which funds bought and sold →

Largest reported holders, June 30, 2026
Manager Value Shares Share of 13F value Shares QoQ
RA Capital Management, L.P. $18.2M 4.0M 11.4% 0.0%
Bvf Inc $14.8M 3.2M 9.3% ▲ 63.5%
Acorn Capital Advisors, LLC $12.9M 2.8M 8.1% 0.0%
Stepstone Group LP $12.1M 2.7M 7.6% 0.0%
ADAR1 Capital Management, LLC $10.2M 2.2M 6.4% ▼ 8.1%
Vivo Capital, LLC $8.8M 1.9M 5.5% 0.0%
Vestal Point Capital, LP $8.3M 1.8M 5.2% ▼ 0.8%
Blackrock, Inc. $6.8M 1.5M 4.3% ▲ 2924.7%
Trails Edge Capital Partners, LP $6.6M 1.4M 4.1% New
Vanguard Capital Management LLC $6.6M 1.4M 4.1% ▲ 146.7%
Adage Capital Partners Gp, L.L.C. $5.5M 1.2M 3.4% 0.0%
Citadel Advisors LLC $5.4M 1.2M 3.4% ▲ 3058.1%

From Form 13F filings with the SEC ( quarterly data sets), as reported by each manager for June 30, 2026 and filed up to 45 days later. 13F reports cover long US-listed positions of managers above $100M only, so this is not Onkure Therapeutics, Inc.'s complete shareholder register. Values are as reported by the filers .

Insider trading activity

Full insider history and chart
Insider purchases History → $0 0 trades by 0 insiders, last 12 months Insider sales History → $5,632 8 trades by 2 insiders · 0% under pre-set plans
Net ▼ $5,632 net selling
Insider Date Trade Shares Price Value
Leverone Jason A. Chief Financial Officer September 21, 2026 Sell 302 $2.97 $897
Saccomano Nicholas A President and CEO September 21, 2026 Sell 87 $2.97 $258
Leverone Jason A. Chief Financial Officer June 22, 2026 Sell 303 $4.40 $1,333
Saccomano Nicholas A President and CEO June 22, 2026 Sell 86 $4.40 $378
Leverone Jason A. Chief Financial Officer March 23, 2026 Sell 301 $4.16 $1,252
Saccomano Nicholas A President and CEO March 23, 2026 Sell 86 $4.16 $358
Leverone Jason A. Chief Financial Officer December 22, 2025 Sell 302 $2.97 $897
Saccomano Nicholas A President and CEO December 22, 2025 Sell 87 $2.97 $258

From insiders' Form 4 filings with the SEC. Excludes awards, option exercises and shares withheld for tax. "Pre-set plan" means the filing marks the trade as made under a Rule 10b5-1 plan. See every insider trade since five years ago, on a price chart.

Earnings dates and SEC filings

Results announcements

Next expected around November 5, 2026 estimated from the company's past filing pattern, not announced

  • August 4, 2026
  • May 5, 2026
  • March 12, 2026
  • November 6, 2025
  • August 12, 2025
  • May 6, 2025

Recent SEC filings

Data status

When each part of this page on Onkure Therapeutics, Inc. was last updated.

DataLast updatedSource
Share priceExchange closing prices
News and updatesCompany releases and SEC 8-K filings
Analyst estimatesAggregated analyst estimates
Valuation and scoresOur models, from the filed figures

How we build and check these figures: methodology and data sources.

Onkure Therapeutics, Inc. in brief

What does Onkure Therapeutics, Inc. do?
Onkure Therapeutics, Inc. is a US-listed company in the biotechnology industry. Its financial year ends in December.
What is Onkure Therapeutics, Inc.'s stock ticker?
Onkure Therapeutics, Inc. trades under the ticker OKUR on Nasdaq. This page brings together its financial statements, valuation models, ownership and recent company updates.
Who are Onkure Therapeutics, Inc.'s largest institutional shareholders?
By value reported in 13F filings for June 30, 2026, the largest reported holders are RA Capital Management, L.P., Bvf Inc and Acorn Capital Advisors, LLC. 13F reports cover long US-listed positions of managers above $100M, filed up to 45 days after quarter end.
Are insiders buying or selling Onkure Therapeutics, Inc. stock?
Over the last 12 months, Onkure Therapeutics, Inc.'s directors and officers reported 0 open-market purchases and 8 sales on Form 4. The insider trading page charts every trade.
When is Onkure Therapeutics, Inc.'s next earnings date?
Around November 5, 2026, estimated from the spacing of its past results announcements (8-K filings). That is an estimate, not a confirmed date — Onkure Therapeutics, Inc. announces its own schedule.